Alnylam Pharmaceuticals (ALNY) Projected to Release Quarterly Earnings on Thursday

Alnylam Pharmaceuticals (NASDAQ:ALNY) is projected to post its Q3 2026 results before the market opens on Thursday, October 29th. Analysts expect Alnylam Pharmaceuticals to announce earnings of $1.70 per share and revenue of $1.43 billion for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, October 29, 2026 at 8:30 AM ET.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 EPS for the quarter, topping analysts’ consensus estimates of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%. The company had revenue of $1.29 billion for the quarter, compared to analysts’ expectations of $1.32 billion. During the same period in the prior year, the firm earned ($0.51) earnings per share. The firm’s revenue was up 66.9% compared to the same quarter last year. On average, analysts expect Alnylam Pharmaceuticals to post $6.66 EPS for the current fiscal year and $9.61 EPS for the next fiscal year.

Alnylam Pharmaceuticals Stock Down 2.4%

NASDAQ:ALNY opened at $225.10 on Thursday. Alnylam Pharmaceuticals has a 52 week low of $197.81 and a 52 week high of $485.36. The stock’s fifty day moving average is $239.89 and its two-hundred day moving average is $272.01. The stock has a market capitalization of $30.12 billion, a price-to-earnings ratio of 41.84 and a beta of 0.28. The company has a quick ratio of 2.99, a current ratio of 3.05 and a debt-to-equity ratio of 0.75.

Insider Transactions at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Bryan Supran sold 1,758 shares of the firm’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total value of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently weighed in on ALNY shares. TD Cowen reaffirmed a “buy” rating on shares of Alnylam Pharmaceuticals in a research note on Monday, August 31st. Raymond James Financial raised Alnylam Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a $420.00 target price on the stock in a research note on Monday, August 3rd. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, July 31st. Stifel Nicolaus lowered their target price on Alnylam Pharmaceuticals from $444.00 to $318.00 and set a “buy” rating for the company in a report on Friday, July 31st. Finally, Wells Fargo & Company dropped their target price on Alnylam Pharmaceuticals from $256.00 to $253.00 and set an “equal weight” rating for the company in a research report on Wednesday, October 14th. Four equities research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $364.95.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.